Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells. 2018

Alexei F Kirkin, and Karine N Dzhandzhugazyan, and Per Guldberg, and Johnny Jon Fang, and Rikke S Andersen, and Christina Dahl, and Jann Mortensen, and Tim Lundby, and Aase Wagner, and Ian Law, and Helle Broholm, and Line Madsen, and Christer Lundell-Ek, and Morten F Gjerstorff, and Henrik J Ditzel, and Martin R Jensen, and Walter Fischer
Danish Cancer Society Research Center, 2100, Copenhagen, Denmark. aki@cytovac.dk.

In cancer cells, cancer/testis (CT) antigens become epigenetically derepressed through DNA demethylation and constitute attractive targets for cancer immunotherapy. Here we report that activated CD4+ T helper cells treated with a DNA-demethylating agent express a broad repertoire of endogenous CT antigens and can be used as antigen-presenting cells to generate autologous cytotoxic T lymphocytes (CTLs) and natural killer cells. In vitro, activated CTLs induce HLA-restricted lysis of tumor cells of different histological types, as well as cells expressing single CT antigens. In a phase 1 trial of 25 patients with recurrent glioblastoma multiforme, cytotoxic lymphocytes homed to the tumor, with tumor regression ongoing in three patients for 14, 22, and 27 months, respectively. No treatment-related adverse effects were observed. This proof-of-principle study shows that tumor-reactive effector cells can be generated ex vivo by exposure to antigens induced by DNA demethylation, providing a novel, minimally invasive therapeutic strategy for treating cancer.

UI MeSH Term Description Entries
D008297 Male Males
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D005260 Female Females
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006377 T-Lymphocytes, Helper-Inducer Subpopulation of CD4+ lymphocytes that cooperate with other lymphocytes (either T or B) to initiate a variety of immune functions. For example, helper-inducer T-cells cooperate with B-cells to produce antibodies to thymus-dependent antigens and with other subpopulations of T-cells to initiate a variety of cell-mediated immune functions. Helper Cell,Helper Cells,Helper T Cell,Helper-Inducer T-Lymphocytes,Inducer Cell,Inducer Cells,T-Cells, Helper-Inducer,T-Lymphocytes, Helper,T-Lymphocytes, Inducer,Helper T-Cells,Cell, Helper T,Cells, Helper T,Helper Inducer T Lymphocytes,Helper T Cells,Helper T-Cell,Helper T-Lymphocyte,Helper T-Lymphocytes,Helper-Inducer T-Cell,Helper-Inducer T-Cells,Helper-Inducer T-Lymphocyte,Inducer T-Lymphocyte,Inducer T-Lymphocytes,T Cell, Helper,T Cells, Helper,T Cells, Helper Inducer,T Lymphocytes, Helper,T Lymphocytes, Helper Inducer,T Lymphocytes, Inducer,T-Cell, Helper,T-Cell, Helper-Inducer,T-Cells, Helper,T-Lymphocyte, Helper,T-Lymphocyte, Helper-Inducer,T-Lymphocyte, Inducer
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000938 Antigen-Presenting Cells A heterogeneous group of immunocompetent cells that mediate the cellular immune response by processing and presenting antigens to the T-cells. Traditional antigen-presenting cells include MACROPHAGES; DENDRITIC CELLS; LANGERHANS CELLS; and B-LYMPHOCYTES. FOLLICULAR DENDRITIC CELLS are not traditional antigen-presenting cells, but because they hold antigen on their cell surface in the form of IMMUNE COMPLEXES for B-cell recognition they are considered so by some authors. Accessory Cells, Immunologic,Antigen-Presenting Cell,Immunologic Accessory Cells,Accessory Cell, Immunologic,Cell, Immunologic Accessory,Cells, Immunologic Accessory,Immunologic Accessory Cell,Antigen Presenting Cell,Antigen Presenting Cells,Cell, Antigen-Presenting,Cells, Antigen-Presenting

Related Publications

Alexei F Kirkin, and Karine N Dzhandzhugazyan, and Per Guldberg, and Johnny Jon Fang, and Rikke S Andersen, and Christina Dahl, and Jann Mortensen, and Tim Lundby, and Aase Wagner, and Ian Law, and Helle Broholm, and Line Madsen, and Christer Lundell-Ek, and Morten F Gjerstorff, and Henrik J Ditzel, and Martin R Jensen, and Walter Fischer
June 2010, Archivum immunologiae et therapiae experimentalis,
Alexei F Kirkin, and Karine N Dzhandzhugazyan, and Per Guldberg, and Johnny Jon Fang, and Rikke S Andersen, and Christina Dahl, and Jann Mortensen, and Tim Lundby, and Aase Wagner, and Ian Law, and Helle Broholm, and Line Madsen, and Christer Lundell-Ek, and Morten F Gjerstorff, and Henrik J Ditzel, and Martin R Jensen, and Walter Fischer
April 2009, Current opinion in immunology,
Alexei F Kirkin, and Karine N Dzhandzhugazyan, and Per Guldberg, and Johnny Jon Fang, and Rikke S Andersen, and Christina Dahl, and Jann Mortensen, and Tim Lundby, and Aase Wagner, and Ian Law, and Helle Broholm, and Line Madsen, and Christer Lundell-Ek, and Morten F Gjerstorff, and Henrik J Ditzel, and Martin R Jensen, and Walter Fischer
January 2016, Immunopharmacology and immunotoxicology,
Alexei F Kirkin, and Karine N Dzhandzhugazyan, and Per Guldberg, and Johnny Jon Fang, and Rikke S Andersen, and Christina Dahl, and Jann Mortensen, and Tim Lundby, and Aase Wagner, and Ian Law, and Helle Broholm, and Line Madsen, and Christer Lundell-Ek, and Morten F Gjerstorff, and Henrik J Ditzel, and Martin R Jensen, and Walter Fischer
January 2010, Cancer journal (Sudbury, Mass.),
Alexei F Kirkin, and Karine N Dzhandzhugazyan, and Per Guldberg, and Johnny Jon Fang, and Rikke S Andersen, and Christina Dahl, and Jann Mortensen, and Tim Lundby, and Aase Wagner, and Ian Law, and Helle Broholm, and Line Madsen, and Christer Lundell-Ek, and Morten F Gjerstorff, and Henrik J Ditzel, and Martin R Jensen, and Walter Fischer
January 2002, Cancer chemotherapy and biological response modifiers,
Alexei F Kirkin, and Karine N Dzhandzhugazyan, and Per Guldberg, and Johnny Jon Fang, and Rikke S Andersen, and Christina Dahl, and Jann Mortensen, and Tim Lundby, and Aase Wagner, and Ian Law, and Helle Broholm, and Line Madsen, and Christer Lundell-Ek, and Morten F Gjerstorff, and Henrik J Ditzel, and Martin R Jensen, and Walter Fischer
October 2014, Oncoimmunology,
Alexei F Kirkin, and Karine N Dzhandzhugazyan, and Per Guldberg, and Johnny Jon Fang, and Rikke S Andersen, and Christina Dahl, and Jann Mortensen, and Tim Lundby, and Aase Wagner, and Ian Law, and Helle Broholm, and Line Madsen, and Christer Lundell-Ek, and Morten F Gjerstorff, and Henrik J Ditzel, and Martin R Jensen, and Walter Fischer
December 2022, Science advances,
Alexei F Kirkin, and Karine N Dzhandzhugazyan, and Per Guldberg, and Johnny Jon Fang, and Rikke S Andersen, and Christina Dahl, and Jann Mortensen, and Tim Lundby, and Aase Wagner, and Ian Law, and Helle Broholm, and Line Madsen, and Christer Lundell-Ek, and Morten F Gjerstorff, and Henrik J Ditzel, and Martin R Jensen, and Walter Fischer
August 2005, Cancer immunology, immunotherapy : CII,
Alexei F Kirkin, and Karine N Dzhandzhugazyan, and Per Guldberg, and Johnny Jon Fang, and Rikke S Andersen, and Christina Dahl, and Jann Mortensen, and Tim Lundby, and Aase Wagner, and Ian Law, and Helle Broholm, and Line Madsen, and Christer Lundell-Ek, and Morten F Gjerstorff, and Henrik J Ditzel, and Martin R Jensen, and Walter Fischer
September 2001, Current gene therapy,
Alexei F Kirkin, and Karine N Dzhandzhugazyan, and Per Guldberg, and Johnny Jon Fang, and Rikke S Andersen, and Christina Dahl, and Jann Mortensen, and Tim Lundby, and Aase Wagner, and Ian Law, and Helle Broholm, and Line Madsen, and Christer Lundell-Ek, and Morten F Gjerstorff, and Henrik J Ditzel, and Martin R Jensen, and Walter Fischer
January 2016, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Copied contents to your clipboard!